• Explore /
  • Poster
  • / A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.

A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.

Abstract Poster

Authors

null

Hope S. Rugo

Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Hope S. Rugo , Javier Cortes , Binghe Xu , Chiun-Sheng Huang , Sung-Bae Kim , Michelle E. Melisko , Rita Nanda , Priyanka Sharma , Richard Schwab , Pei Hsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03562637

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS611)

DOI

10.1200/JCO.2022.40.16_suppl.TPS611

Abstract #

TPS611

Poster Bd #

380a

Abstract Disclosures

Similar Posters

First Author: Naureen Starling

First Author: Sara M. Tolaney

First Author: Erika P. Hamilton

First Author: Erika P. Hamilton